ENDURANCE Trail for Patients with Newly Diagnosed Symptomatic Multiple Myeloma

Description:

The purpose of this study is to compare the effects, good and/or bad, of a combination of carfilzomib, lenalidomide and dexamethasone with a combination of bortezomib, lenalidomide and dexamethasone in patients newly diagnosed with symptomatic multiple myeloma.

I'M INTERESTED

Contact: Katie Colbeck, 413-794-9875

Participation details:

Start Date: December 03, 2013

IRB Number: 542574

Condition/Disease: Cancer, Cancer - Multiple Myeloma

Location:

D’Amour Center for Cancer Care, 3350 Main Street, Springfield, MA

Eligibility:

Patients with newly diagnosed multiple myeloma

Status: Recruiting

Current Trial Type: Interventional (Clinical Trial), Randomized

Phase: 3